The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure
Open accessAbstract
The current study assesses the antihypertensive efficacy and safety of the investigational angiotensin receptor blocker (ARB), azilsartan medoxomil (AZL‐M), compared with placebo and the ARB olmesartan medoxomil (OLM‐M). This randomized, double‐blind, placebo‐controlled, multicenter study assessed change from baseline in mean 24‐hour ambulatory systolic blood pressure (SBP) following 6 weeks of treatment. Patients with primary hypertension ( n =1275) and baseline 24‐hour mean ambulatory systolic pressure ≥130 mm Hg and ≤170 mm Hg were studied; 142 received placebo and the remainder received 20 mg, 40 mg, or 80 mg AZL‐M or 40 mg OLM‐M. Mean age of participants was 58±11 years, baseline mean 24‐hour SBP was 146 mm Hg. Dose‐dependent reductions in 24‐hour mean SBP at study end occurred in all AZL‐M groups. Reduction in 24‐hour mean SBP was greater with AZL‐M 80 mg than OLM‐M 40 mg by 2.1 mm Hg (95% confidence interval, −4.0 to −0.1; P=.038), while AZL‐M 40 mg was noninferior to OLM‐M 40 mg. The side effect profiles of both ARBs were similar to placebo. AZL‐M is well tolerated and more efficacious at its maximal dose than the highest dose of OLM‐M. J Clin Hypertens (Greenwich). 2011;13:81–88. © 2011 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Specifically, 24-hour ABPM studies demonstrate that azilsartan medoximil provides on average an additional 4 to 8 mm Hg further SBP reduction over other ARBs (eg, valsartan and olmesartan) or the ACE inhibitor ramipril.381–383”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [382]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association
Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31823ac046 · Cited by 7,333
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
HEART DISEASE AND STROKE STATISTICS–2014 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION
Tarver, T. (2014) · Journal of Consumer Health on the Internet · doi:10.1080/15398285.2014.902284 · Cited by 5,595
US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008
Egan, B. M. (2010) · JAMA · doi:10.1001/jama.2010.650 · Cited by 2,197
Pfeffer, M. A., Swedberg, K. B., Granger, C. B., Held, P., McMurray, J. J. V., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,895
Pitt, B., Segal, R., Martínez, F. A., Meurers, G., Cowley, A. J., Thomas, I., DEEDWANIA, P. C., Ney, D. E., Snavely, D. B., & Chang, P. (1997) · The Lancet · doi:10.1016/s0140-6736(97)01187-2 · Cited by 1,660
Blood Pressure Lowering Treatment Trialists’ Collaboration (2008) · BMJ · doi:10.1136/bmj.39548.738368.be · Cited by 739
Cited by
Sorted by citations
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153
Self-citationThe past, present and future of renin–angiotensin aldosterone system inhibition
Mentz, R. J., Bakris, G. L., Waeber, B., McMurray, J. J. V., Gheorghiade, M., Ruilope, L. M., Maggioni, A. P., Swedberg, K. B., Piña, I. L., Fiuzat, M., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.10.007 · Cited by 121
Self-citationSica, D. A., White, W. B., Weber, M. A., Bakris, G. L., Pérez, A., Cao, C., Handley, A., & Kupfer, S. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00482.x · Cited by 117
“There was a greater likelihood of serum creatinine transiently increasing at any postbaseline visit, a finding not unexpected with the significant BP reduction seen with a potent ARB.(21,22) This finding is likely due to BP-related alterations in renal hemodynamics, as has been previously described in patients treated…”
BackgroundSelf-citationRakugi, H., Enya, K., Sugiura, K., & Ikeda, Y. (2012) · Hypertension Research · doi:10.1038/hr.2012.8 · Cited by 114
Angiotensin Receptor Blockers: Pharmacology, Efficacy, and Safety
Taylor, A. A., Siragy, H. M., & Nesbitt, S. D. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00518.x · Cited by 103
“In a companion study, changes in placebo-subtracted trough seated systolic BP in each of 4 active treatment groups (AZL 20 mg, 40 mg, and 80 mg daily and olmesartan medoxomil 40 mg daily) were similar to the changes in mean ambulatory systolic pressure.(40)”
ResultBakris, G. L., Sica, D., White, W. B., Cushman, W. C., Weber, M. A., Handley, A., Song, E., & Kupfer, S. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.05.023 · Cited by 90
Self-citationAhmadian, E., Khosroushahi, A. Y., Eftekhari, A., Farajnia, S., Babaei, H., & Eghbal, M. A. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.01.117 · Cited by 84
Differential pharmacology and benefit/risk of azilsartan compared to other sartans
Kurtz, T. W., Kajiya, & Kurtz (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s22595 · Cited by 79
“Because the relationship between cardiovascular risk and BP is monotonic with absolute risk decreasing progressively as BP decreases towards recommended goals, the greater antihypertensive effects of azilsartan serve to justify clinical interest in this recently approved ARB relative to other molecules in the class wi…”
InfluentialGhazi, L., & Drawz, P. E. (2017) · F1000Research · doi:10.12688/f1000research.9692.1 · Cited by 72
“Azilsartan, a novel ARB, has been shown to have superior efficacy in reducing blood pressure (BP) when compared with olmesartan or valsartan 14–16 .”
BackgroundAzilsartan Medoxomil: A New Angiotensin II Receptor Antagonist for Treatment of Hypertension
Baker, W. L., & White, W. B. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q468 · Cited by 70
Self-citationCushman, W. C., Bakris, G. L., White, W. B., Weber, M. A., Sica, D. A., Roberts, A., Lloyd, E., & Kupfer, S. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.188284 · Cited by 71
Self-citationAzilsartan Medoxomil: A New Angiotensin Receptor Blocker
Zaiken, K., & Cheng, J. W. M. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.10.007 · Cited by 66
Molecular and cellular effects of azilsartan
Kajiya, T., Ho, C. I., Wang, J., Vilardi, R. F., & Kurtz, T. W. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834c46fd · Cited by 64
Bönner, G., Bakris, G. L., Sica, D., Weber, M. A., White, W. B., Perez, A., Cao, C., Handley, A., & Kupfer, S. (2013) · Journal of Human Hypertension · doi:10.1038/jhh.2013.6 · Cited by 61
Self-citationMiura, S.-I., Okabe, A., Matsuo, Y., Karnik, S. S., & Saku, K. (2012) · Hypertension Research · doi:10.1038/hr.2012.147 · Cited by 60
Key advances in antihypertensive treatment
Paulis, L., Steckelings, U. M., & Unger, T. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.33 · Cited by 53
Perry, C. M. (2012) · Clinical Drug Investigation · doi:10.1007/bf03261917 · Cited by 50
“In the 6-week placebo-controlled trials, the BP-lowering efficacy of azilsartan medoxomil was compared with olmesartan medoxomil([20,21]) and valsartan.”
BackgroundMethodResultInfluentialDiscovery of Inhibitors of Insulin‐Regulated Aminopeptidase as Cognitive Enhancers
Andersson, H., & Hallberg, M. (2012) · International Journal of Hypertension · doi:10.1155/2012/789671 · Cited by 48
Sica, D. A., Bakris, G. L., White, W. B., Weber, M. A., Cushman, W. C., Huang, P., Roberts, A., & Kupfer, S. (2012) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2012.00616.x · Cited by 46
Self-citationSueta, D., Kataoka, K., Koibuchi, N., Toyama, K., Uekawa, K., Katayama, T., Ma, M., Nakagawa, T., Waki, H., Maeda, M., et al. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000035 · Cited by 37
White, W. B., Cuadra, R. H., Lloyd, E., Bakris, G. L., & Kupfer, S. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000839 · Cited by 37
“Two of the three trials used for this analysis [11,12] were of 6 weeks duration, and ambulatory BP monitoring was performed at baseline and following 6 weeks of doubleblind therapy.”
MethodSelf-citationBronson, J. J., Dhar, T. G. M., Ewing, W. R., & Lönberg, N. (2012) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-396492-2.00031-x · Cited by 33
Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker.
Jones, J. D., Jackson, S., Agboton, C., & Martin, T. S. (2011) · Europe PMC (PubMed Central) · Cited by 33
A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction
for the ALICE (All-Literature Investigation of Cardiovascular Evidence) Group, Takagi, H., Mizuno, Y., Niwa, M., Goto, S.-N., & Umemoto, T. (2013) · Hypertension Research · doi:10.1038/hr.2013.142 · Cited by 32
Azilsartan Decreases Renal and Cardiovascular Injury in the Spontaneously Hypertensive Obese Rat
Khan, A. H., Neckář, J., Cummens, B., Wahl, G., & Imig, J. D. (2014) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-014-6530-0 · Cited by 30
Farsang, C. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s23468 · Cited by 30
Amin, R. R. H., & Aziz, T. A. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s365090 · Cited by 29
“Azilsartan has an oxooxadiazole ring that is absent from other clinically authorized ARBs, making it less acidic and more lipophilic than other ARBs.20 Studies showed the superiority of azilsartan as antihypertensive when compared with other ARBs.21,22 Some ARBs proven to have gastroprotective effects, however, the in…”
ResultAngeloni, E. (2016) · Core evidence · doi:10.2147/ce.s81776 · Cited by 27
Vekariya, P. P., & Joshi, H. S. (2013) · ISRN Spectroscopy · doi:10.1155/2013/572170 · Cited by 26
Azilsartan: Current Evidence and Perspectives in Management of Hypertension
Pradhan, A. K., Tiwari, A., & Sethi, R. (2019) · International Journal of Hypertension · doi:10.1155/2019/1824621 · Cited by 29
“In this study, azilsartan was well tolerated and more efficacious at its maximal dose than the highest dose of olmesartan medoxomil [14].”
BackgroundMethodfor the EARLY Registry Group, Gitt, A. K., Bramlage, P., Potthoff, S. A., Baumgart, P., Mahfoud, F., Buhck, H., Ehmen, M., Ouarrak, T., Senges, J., et al. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0222-6 · Cited by 25
“As AZL-M has demonstrated higher efficacy for BP lowering in comparison to other sartans, it is unsurprising that it has performed better in the patients included in the EARLY registry [4, 9, 11, 24].”
BackgroundResultGeorgiopoulos, G. A., Katsi, V. K., Oikonomou, D., Vamvakou, G. D., Koutli, E., Laina, A., Tsioufis, C., Nihoyannopoulos, P., & Tousoulis, D. M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00235 · Cited by 24
“Based on the results of up-to date clinical trials (Bakris et al., 2011, 2012; Sica et al., 2011, 2012; White et al., 2011; Cushman et al., 2012; Rakugi et al., 2012, 2014; Bönner et al., 2013; Weber et al., 2014b; Kario and Hoshide, 2015; Kipnes et al., 2015; Gitt et al., 2016), AZL-M is a potent…”
BackgroundResultInfluentialWang, J., Zhang, M., Feng, Y., Ma, C., Wang, T., Zhu, Z., & Kario, K. (2021) · Journal of Clinical Hypertension · doi:10.1111/jch.14227 · Cited by 23
Special Article - The management of resistant hypertension: A 2020 update
Carey, R. M. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.08.001 · Cited by 23
Critical evaluation of the efficacy and tolerability of azilsartan
Caterina, A. D., Harper, A. R., & Cuculi (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s22589 · Cited by 22
“In terms of tolerability, azilsartan was very well tolerated, as the incidence of the most commonly reported adverse events (ie, headache, dyslipidemia, and dizziness) were reported to be similar compared to the placebo and candesartan groups.(34) In another study of 1291 subjects, where the mean systolic BP before tr…”
ResultAngeli, F., Verdecchia, P., Pascucci, C., Poltronieri, C., & Reboldi, G. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.769521 · Cited by 22
“Four studies [24-27] comparing the efficacy of azilsartan with other ARBs have been published in the literature to date (Figure 1).”
BackgroundResultInfluentialLam, S. (2011) · Cardiology in Review · doi:10.1097/crd.0b013e31822e9ba3 · Cited by 22
“The adverse effect rates (41%–51%) were comparable to that of olmesartan (38%–52%) and valsartan (47%).(17,18) Although no cases of hyperkalemia were reported, it is prudent to monitor because hyperkalemia might be a class effect of all ARBs, especially in long-term use.”
BackgroundResultInfluentialAzilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension
Hjermitslev, M. H., Grimm, D. G., Wehland, M., Simonsen, U., & Krüger, M. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12800 · Cited by 22
Azilsartan/chlorthalidone combination therapy for blood pressure control
Cheng, J. W. M. (2013) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s34792 · Cited by 17
Bakris, G. L., Zhao, L., Kupfer, S., Juhász, A., Hisada, M., Lloyd, E., & Oparil, S. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13230 · Cited by 16
Self-citationEffects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension
Weber, M. A., White, W. B., Sica, D. A., Bakris, G. L., Cao, C., Roberts, A., & Kupfer, S. (2014) · Blood Pressure Monitoring · doi:10.1097/mbp.0000000000000027 · Cited by 17
Self-citationShiga, Y., Miura, S., Motozato, K., Norimatsu, K., Yano, M., Hitaka, Y., Adachi, S., Kuwano, T., Inoue, K., Inoue, A., et al. (2017) · International Heart Journal · doi:10.1536/ihj.16-285 · Cited by 17
Kourlaba, G., Gialama, F., Tsioufis, K., & Maniadakis, N. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.115 · Cited by 16
Preston, R. A., Karim, A., Dudkowski, C., Zhao, Z., Garg, D. C., Lenz, O., & Sica, D. A. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0044-y · Cited by 14
“Azilsartan medoxomil (AZL-M) is a potent, long-acting ARB that effectively decreases BP in a dosedependent manner in subjects with mild to moderate hypertension [15–17].”
BackgroundSelf-citationOut-of-office blood pressure: from measurement to control
Baguet, J.-P. (2012) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s30409 · Cited by 16
Pérez, A., & Cao, C. (2016) · Journal of Clinical Hypertension · doi:10.1111/jch.12873 · Cited by 14
Self-citationSezai, A., Osaka, S., Yaoita, H., Arimoto, M., Hata, H., Shiono, M., & Sakino, H. (2016) · Annals of Thoracic and Cardiovascular Surgery · doi:10.5761/atcs.oa.16-00054 · Cited by 13
Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases
Balakumar, P., & Jagadeesh, G. (2015) · Springer eBooks · doi:10.1007/978-3-319-15961-4_36 · Cited by 12
Nie, Y.-Y., Da, Y., Zheng, H., Yang, X., Jia, L., Wen, C.-H., Liang, L.-S., Tian, J., & Chen, Z. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.02.003 · Cited by 12
Miura, S.-I., Matsuo, Y., Nakayama, A., Tomita, S., Suematsu, Y., & Saku, K. (2013) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320313482170 · Cited by 12
Nedogoda, S. V., Chumachek, E. V., Цома, В. В., Salasyuk, A. S., Smirnova, V. O., & Popova, E. A. (2019) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2019-1-70-79 · Cited by 12
Gong, C., Wang, J., Sun, Y. H., Ding, D., Zhong, L., Zhu, M., Sun, J., & Zhang, X. (2014) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2014.10.004 · Cited by 11
Harrell, R. E., Karim, A., Zhang, W., & Dudkowski, C. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0333-8 · Cited by 11
Cushman, W. C., Bakris, G. L., White, W. B., Weber, M. A., Sica, D. A., Roberts, A., Lloyd, E., & Kupfer, S. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001647 · Cited by 11
Self-citationfor the EARLY Registry Group, Gitt, A. K., Baumgart, P., Bramlage, P., Mahfoud, F., Potthoff, S. A., Senges, J., Schneider, S., Buhck, H., & Schmieder, R. E. (2013) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-13-46 · Cited by 10
“AZM at a dose of 80 mg once daily provided superior BP lowering compared to the highest approved doses of olmesartan (40 mg), valsartan (320 mg) and candesartan (32 mg) [6-9] (Table 1).”
BackgroundShould Two-Drug Initial Therapy for Hypertension Be Recommended for All Patients?
Cowart, J. B., & Taylor, A. A. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0280-9 · Cited by 10
Handley, A., Lloyd, E., Roberts, A., & Barger, B. (2016) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2015.1081213 · Cited by 10
Self-citationClinical utility of azilsartan–chlorthalidone fixed combination in the management of hypertension
Shuster, J. E., Shuster, J. E., & Bleske (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s22583 · Cited by 10
“13,14 This study assessed the same endpoints of mean 24-hour BP, clinical BP, and percentage of responding patients.”
Kher, M. N., Bhatt, V. D., Jani, A., & Sheth, N. R. (2020) · Analytical Chemistry Letters · doi:10.1080/22297928.2020.1784788 · Cited by 9
In Vitro Drug Repurposing: Focus on Vasodilators
Ribeiro, E., Costa, B., Vasques‐Nóvoa, F., & Vale, N. (2023) · Cells · doi:10.3390/cells12040671 · Cited by 9
“Azilsartan was the eighth approved ARB for the management of hypertension in February 2011 [160,161].”
BackgroundLanier, G. M., Sankholkar, K., & Aronow, W. S. (2012) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31824a0ed7 · Cited by 9
“There were similar diastolic BP (DBP) reductions between the groups studied.(17) Responder rates, as defined as treatment to SBP ,140 mm Hg and/or reduction .”
BackgroundResultJuhász, A., Wu, J., Hisada, M., Tsukada, T., & Jeong, M. H. (2018) · Clinical Hypertension · doi:10.1186/s40885-018-0086-4 · Cited by 9
“In this study, patients were enrolled and blood pressure was evaluated using sitting clinic blood pressure, whereas the enrollment eligibility and the primary endpoint in the previous global study [16] were determined through ambulatory blood pressure monitoring.”
BackgroundMethodResultInfluentialWu, J., Du, X., Lv, Q., Li, Z., Zheng, Z., Xia, Y., Tang, C., Yao, Z., Zhang, J., Long, M., et al. (2020) · Medicine · doi:10.1097/md.0000000000021465 · Cited by 9
“The design of this study was closely modeled upon previous studies comparing AZL-M with valsartan as well as the global pivotal study([18]) that”
BackgroundMethodResultInfluentialPossible benefits of azilsartan compared with other angiotensin II type 1 receptor blockers
Miura, S.-I., & Saku, K. (2014) · Hypertension Research · doi:10.1038/hr.2014.118 · Cited by 8
Pérez, A., & Cao, C. (2016) · Journal of Clinical Hypertension · doi:10.1111/jch.12895 · Cited by 8
Self-citationPrevention of Coronary Artery Disease: Recent Advances in the Management of Hypertension
Recarti, C., & Unger, T. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0311-2 · Cited by 8
Azilsartan Medoxomil/Chlorthalidone: A New Fixed-Dose Combination Antihypertensive
Pierini, D., & Anderson, K. V. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r618 · Cited by 9
Suehiro, T., Tsuruya, K., Yoshida, H., Tsujikawa, H., Yamada, S., Tanaka, S., Tsuchimoto, A., Eriguchi, M., Fujisaki, K., Torisu, K., et al. (2021) · Kidney & Blood Pressure Research · doi:10.1159/000512365 · Cited by 8
Ferdinand, K. C., Bakris, G. L., Cushman, W. C., Weber, M. A., Lloyd, E., Wu, J., & White, W. B. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.07.022 · Cited by 8
Self-citationAzilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
Barrios, V., & Escobar, C. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.834887 · Cited by 7
“Angiotensinconverting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) are the most common renin angiotensin system inhibitors prescribed for the treatment of hypertension in daily clinical practice [15].”
InfluentialZhao, D., Liu, H., & Dong, P. (2018) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-018-1859-1 · Cited by 7
Johnson, W. R., White, W. B., Sica, D. A., Bakris, G. L., Weber, M. A., Handley, A., Pérez, A., Cao, C., Kupfer, S., & Saunders, E. (2017) · Journal of Clinical Hypertension · doi:10.1111/jch.12993 · Cited by 7
Self-citationGarg, M., Manik, G., Singhal, A., Singh, V., Varshney, R. K., & Sethi, A. (2020) · Saudi Journal of Medicine and Medical Sciences · doi:10.4103/sjmms.sjmms_19_19 · Cited by 7
“In terms of 24‐h mean ambulatory SBP, Bakris et al.[26] found that treatment with 60 70 80 90 100 110 120 130 140”
BackgroundInfluentialSeo, S. M., Ihm, S., Yi, J., Jeong, S. H., & Kim, B. (2022) · Journal of Clinical Hypertension · doi:10.1111/jch.14536 · Cited by 7
Kipnes, M. S., Handley, A., Lloyd, E., Barger, B., & Roberts, A. (2015) · Journal of Clinical Hypertension · doi:10.1111/jch.12474 · Cited by 6
Self-citationKwon, A., & Kim, G.-H. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.05.015 · Cited by 6
An evaluation of the latest evidence relating to renin–angiotensin system inhibitors
Escobar, C., & Barrios, V. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.788149 · Cited by 6
“[62] Patients were randomized to placebo, azilsartan 20 mg, 40 mg, or 80 mg or olmesartan 40 mg A dose-dependent reduction was observed in 24 h mean systolic BP with azilsartan 24 h mean systolic BP reduction was higher with azilsartan 80 mg compared with olmesartan 40 mg (D-2.”
BackgroundMethodEfficacy of azilsartan medoxomil with chlorthalidone in hypertension
Baker, W. L., Nigro, S. C., & White, W. B. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.924853 · Cited by 6
“AZL was compared with olmesartan in two trials [17,18], valsartan in two trials [18,19], candesartan in one trial versus azilsartan (rather than AZL like the other trials) [20] and ramipril in one trial [21].”
MethodSelf-citationAdachi, S., Miura, S., Shiga, Y., Arimura, T., Kuwano, T., Kitajima, K., Ike, A., Sugihara, M., Iwata, A., Nishikawa, H., et al. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2675w · Cited by 6
Collier, D., Juhász, A., Agabiti‐Rosei, E., Lloyd, E., Hisada, M., Zhao, L., Kupfer, S., & Caulfield, M. J. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13376 · Cited by 6
Self-citationHypertension Therapeutics Update: A Brief Clinical Summary on Azilsartan, Cilnidipine and Nebivolol
Sharma, S. (2015) · Hypertension Journal · doi:10.5005/jp-journals-10043-0019 · Cited by 5
Practical efficacy of olmesartan versus azilsartan in patients with hypertension
Kakio, Y., Uchida, H. A., Umebayashi, R., Takeuchi, H., Okuyama, Y., Hanayama, Y., & Wada, J. (2017) · Blood Pressure Monitoring · doi:10.1097/mbp.0000000000000229 · Cited by 5
Can the effectiveness of hypertension management be improved?
Ruilope, L. M. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.13.18 · Cited by 5
for the EARLY Registry Group, Bramlage, P., Schmieder, R. E., Gitt, A. K., Baumgart, P., Mahfoud, F., Buhck, H., Ouarrak, T., Ehmen, M., & Potthoff, S. A. (2015) · Trials · doi:10.1186/s13063-015-1100-8 · Cited by 5
“Azilsartan medoxomil (AZL-M) is a more recently approved ARB that has been intensively studied in a number of clinical trials [3–8].”
BackgroundA randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone
Weber, M. A., Sever, P., Juhász, A., Roberts, A., & Cao, C. (2018) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320318795000 · Cited by 5
Self-citationTamura, K., Ohsawa, M., Kanaoka, T., Maeda, A., Azushima, K., Uneda, K., Wakui, H., Azuma, K., Tsurumi‐Ikeya, Y., & Umemura, S. (2012) · Hypertension Research · doi:10.1038/hr.2012.166 · Cited by 4
Peraman, R., Dakinedi, S. R., Kadiri, R. R., & Malineni, L. (2017) · Journal of Young Pharmacists · doi:10.5530/jyp.2017.9.39 · Cited by 4
Xu, H., Kang, L., Qin, J., Lin, J., Xue, M., & Meng, Z. (2020) · ACS Omega · doi:10.1021/acsomega.0c00156 · Cited by 4
Katsi, V. K., Michalakeas, C. A., Σουλαϊδόπουλος, Σ., Antonopoulos, A. S., Vlachopoulos, C. V., Tousoulis, D., & Tsioufis, K. P. (2021) · Current Hypertension Reviews · doi:10.2174/1573402117666210112144505 · Cited by 4
Deerochanawong, C., Chang, K., Woo, Y. C., Lai, W., & Chutinet, A. (2022) · International Journal of Hypertension · doi:10.1155/2022/2717291 · Cited by 3
“)e safety and tolerability profile of AZL-M was consistent with the results from clinical studies conducted in other racial/ ethnic groups [16,17,19].”
BackgroundResultCombination Therapy in Hypertension Treatment
Oliva, R., & Bakris, G. L. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3694-2_12 · Cited by 3
“It is not currently aligned with any SPC containing an ACE-I or ARB, but the combination of the new ARB azilsartan [ 34 ] plus chlorthalidone will be available in the future.”
BackgroundSelf-citationNewer renin–angiotensin–aldosterone system blocker combinations
Lazich, I., & Bakris, G. L. (2011) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3283495819 · Cited by 3
Self-citationEfficacy and safety of different doses of azilsartan medoxomil in patients with hypertension
Zhang, Y., Yu, H., Shao, K., Luo, X., Wang, J., & Chen, G. (2019) · Medicine · doi:10.1097/md.0000000000017050 · Cited by 3
Chazova, I. E., & Zhernakova, Y. V. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1844647 · Cited by 3
Khan, Q. A., Sharma, S. S., Mulk, I. U., Li, D., Belay, N. F., Afzal, M., Farrukh, A. M., Asad, M., Baqi, A., & Semakieh, B. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001547 · Cited by 2
“Six studies utilized an 80 mg dose of Azilsartan for their studies [11 – 13] .”
BackgroundMethodResultInfluentialQian, J., Zhang, M., & Chen, Z. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02997-5 · Cited by 2
Hypertension in metabolic syndrome
Kobalava, Z. D., Конради, А. О., & Nedogoda, S. V. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6536 · Cited by 3
Jones, J. D., Jackson, S., & Colquitt, C. (2013) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s34791 · Cited by 2
“When compared to other ARBs (OLM-M and VAL) and an ACE inhibitor (RAM), AZL-M proved to be more effective at reducing blood pressure.(7,8,10) The greater blood pressure reduction observed may be related to the pharmacologic profile, including slowed AT 1 receptor dissociation and improved receptor specificity.”
Тіазиди або тіазидоподібні діуретики в лікуванні артеріальної гіпертензії?
Радченко, Г. Д. (2018) · HYPERTENSION · doi:10.22141/2224-1485.6.56.2017.120323 · Cited by 2
Lee, H., Hong, B., Su, C. T.-T., Bea, S., Jeong, H. E., Jung, K., Cheng, M. C., Chang, Z. C.-J., Lai, E. C., & Lee, J. (2025) · Epidemiology and Health · doi:10.4178/epih.e2025029 · Cited by 2
“Although previous studies have documented the safety of combining other renin-angiotensin-aldosterone system inhibitors with amlodipine [29,30], direct head-to-head comparisons assessing the safety of combining the high-potency ARB azilsartan medoxomil with amlodipine remain lacking [14,15].”
Metadata
- Authors
- Bakris, G. L., Sica, D., Weber, M., White, W. B., Roberts, A., Perez, A., Cao, C., & Kupfer, S.
- Affiliations
- University of Connecticut (US)
- State University of New York (US)
- Corresponding author
- Bakris, George L.
- Venue
- The Journal of Clinical Hypertension
- Publisher
- Wiley
- Published
- 2011-01-27
- Volume
- 13
- Issue
- 2
- Pages
- 81-88
- ISSN
- 1524-6175 (ISSN-L)
- 1751-7176
- PMC
- PMC8673073
- OpenAlex
- W2077469844
- Cited by
- 143
- References
- 24
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 13 · 2019: 4 · 2018: 12 · 2017: 9 · 2016: 16 · 2015: 7 · 2014: 5 · 2013: 19 · 2012: 21
- FWCI
- 11.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Hypertension (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- PepsiCo
- Gilead Sciences
- FibroGen
- Savient Pharmaceuticals
- Daiichi-Sankyo
- Astellas Pharma
- Servier
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- azilsartan medoxomil, olmesartan medoxomil, angiotensin receptor blockers, antihypertensive efficacy, essential hypertension, 24-hour ambulatory blood pressure, systolic blood pressure, dose-response relationship, drug safety, non-inferiority
- MeSH terms
- Aged, Argentina, Benzimidazoles, Blood Pressure, Blood Pressure Determination, Double-Blind Method, Female, Humans, Hypertension, Imidazoles, Male, Mexico, Middle Aged, Oxadiazoles, Peru, Tetrazoles, United States, Treatment Outcome, Blood Pressure Monitoring, Ambulatory, Racial Groups, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
